首页> 外文期刊>Emerging Infectious Diseases >Alternatives to Ciprofloxacin Use for Enteric Fever, United Kingdom
【24h】

Alternatives to Ciprofloxacin Use for Enteric Fever, United Kingdom

机译:英国肠热用环丙沙星的替代品

获取原文
           

摘要

To the Editor: In cases of ty-phoid and paratyphoid fever, it is of-ten necessary to commence treatment before the results of laboratory sensi-tivity tests are available. It is therefore important to be aware of optional drug therapies available because some or-ganisms may be resistant to key anti-microbial drugs. For typhoid and para-typhoid, cipro. oxacin has become the fi rst-line drug of choice since the widespread emergence and spread of strains resistant to chloramphenicol, ampicillin, and trimethoprim (1).The Laboratory of Enteric Patho-gens (LEP) of the Health Protection Agency of England and Wales is the reference center for Salmonella enter-ica serovars Typhi and Paratyphi A for the United Kingdom; as such, this lab-oratory receives isolates from all cases of infection. Isolates are screened by breakpoint for resistance to antimi-crobial drugs at the following levels: chloramphenicol, 8 mg/L; ampicillin, 8 mg/L; trimethoprim, 2 mg/L; cipro-. oxacin, 0.125 mg/L (decreased sus-ceptibility); and 1.0 mg/L (high-level resistance), ceftriaxone, 1 mg/L, and cefotaxime, 1 mg/L. The levels for testing for resistance to chlorampheni-col, ampicillin, trimethoprim, ceftri-axone, and cefotaxime correspond to internationally accepted therapeutic levels for these antimicrobial agents. In contrast, the levels for cipro. oxa-cin (0.125 and 1.0 mg/L) have been chosen after observations of treatment failures at levels when used at below the expected recommended serum concentrations (2,3). Since 2005, a proportion of isolates exhibiting de-creased susceptibility and high-level resistance to cipro. oxacin have been tested for resistance to azithromycin by Etest (AB Biodisk, Solna, Swe-den), using drug-sensitive strains of S. Typhi and S. Paratyphi A as controls. From January 2001 through De-cember 2006, LEP reported 1,215 cases of S. Typhi infection and 1,274 cases of S. Paratyphi A infection. Of these, ≈60% (1,493) reported recent travel abroad; India and Pakistan were the most frequently visited countries (4). Other cases were associated with persons who had a history of such trav-el, but the numbers involved were dif-fi cult to document accurately because of underreporting of foreign travel and other communication problems
机译:致编辑:如果是伤寒和副伤寒,通常需要在获得实验室敏感性测试结果之前就开始治疗。因此,重要的是要注意可用的可选药物疗法,因为某些有机物可能会对关键的抗微生物药物产生耐药性。对于伤寒和副伤寒,cipro。自从对氯霉素,氨苄青霉素和甲氧苄啶产生抗药性的菌株广泛出现和传播以来,奥沙星已成为首选的第一线药物。英格兰和威尔士卫生防护局的肠道病原菌实验室(LEP)是英国沙门氏菌伤寒沙门氏菌和副伤寒甲的参考中心;因此,该实验室可从所有感染病例中分离出细菌。按断点筛选分离株,以检测以下水平的对抗霉菌药物的耐药性:氯霉素,8 mg / L;氨苄西林8 mg / L;甲氧苄啶2 mg / L; cipro-。奥沙星,0.125 mg / L(敏感性降低); 1.0 mg / L(高水平抗药性),头孢曲松钠1 mg / L和头孢噻肟1 mg / L。对氯霉素,氨苄西林,甲氧苄啶,头孢曲松,头孢噻肟的耐药性检测水平与这些抗微生物剂的国际公认治疗水平相对应。相比之下,cipro的水平。在观察到治疗失败后,以低于预期的推荐血清浓度(2,3)的水平观察到草酸-草酸(0.125和1.0 mg / L)的选择。自2005年以来,一部分分离株表现出降低的敏感性和对cipro的高水平抗药性。 Etest(AB Biodisk,Solna,Swe-den)已使用药敏的伤寒沙门氏菌和副伤寒沙门氏菌A作为对照,测试了奥沙星对阿奇霉素的抗性。从2001年1月到2006年12月,LEP报告了1,215例伤寒沙门氏菌感染和1,274例副伤寒沙门氏菌感染。其中,约60%(1,493)报告最近出国旅行;印度和巴基斯坦是访问量最高的国家(4个)。其他案件与具有此类旅行经历的人有关,但由于未充分报道国外旅行和其他沟通问题,所涉人数难以准确记录

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号